Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Apr 6;11:2007–2015. doi: 10.2147/OTT.S160119

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Zhou et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Butein inhibited HepG2 xenograft growth in vivo.

Notes: (A) The tumor growth curve. (B) The photograph of the tumors. (C) The tumor weights in the vehicle- and the butein-treated group, *p<0.05 versus the vehicle. Nude mice with HepG2 xenograft were randomly assigned into the vehicle or the treatment group, and the treatment was intraperitoneally injected (5 mg/kg butein) three times per week; the tumor volume was recorded twice per week. (D) Body weight of tumor-bearing mice in vehicle- and butein-treated group. (E) The expression of p53 and Ki67 in tumor tissue. The tumor tissue of HepG2 xenograft model was stained through immunohistochemistry with the indicated antibodies. Left: representative images of immunohistochemistry staining. Right: quantification of indicated marker. *p<0.05 indicated significant difference.